NVO - EXCLUSIVE: Vivani Medical Says Weight Loss/Diabetes Implant At Par With Novo Nordisk's Famed Injectable Wegovy/Ozempic Animal Studies Shows | Benzinga
Wednesday, Vivani Medical Inc (NASDAQ:VANI) released preclinical data on weight loss effects for NPM-115, the company’s miniature, twice-yearly exenatide subdermal implant under development for chronic weight management.
In a study in high-fat diet-induced obese mice, NPM-115 generated weight loss of approximately 20% compared to a sham implant control after a 28-day treatment duration.
The company says the weight loss is comparable to that observed in mice treated with Novo Nordisk A/S’s (NYSE:NVO) popular Ozempic/Wegovy injections (semaglutide) in the same study.
The supratherapeutic doses provided for both NPM-115 (single administration delivering exenatide at ~530 nmol/kg/day) and semaglutide (weekly injections of ~2,700 nmol/kg/week) were selected to maximize the weight-loss potential of both exenatide and ...